Focused on Achieving Cures
Kite Pharma (arcellx.com) scores 82 out of 100 on Brand Analyzer, placing it in the Strong Brand tier among Healthcare brands, in the 85th percentile of 19324 Healthcare brands.
Kite Pharma is a biomedical engineering company headquartered in Santa Monica, California, founded in 2009 and now a subsidiary of Gilead Sciences. The company focuses on cancer immunotherapy, specifically developing personalized CAR T-cell therapies that use a patient's own immune system to target and attack cancer cells. Kite's work centers on blood cancers such as lymphoma, aiming to move beyond disease management toward achieving cures through innovative cell therapy research and treatment development.
| Brand Name | Kite Pharma |
|---|---|
| Domain | arcellx.com |
| Industry | Healthcare |
| Founded | 2009 |
| Headquarters | Santa Monica |
| Parent Company / Owner | Gilead Sciences |
| Main Competitors | Novartis (75/100), Bristol Myers Squibb (89/100), Legend Biotech (80/100), Janssen (Johnson & Johnson) (84/100), Autolus Therapeutics (79/100), Allogene Therapeutics (83/100), 2seventy bio (74/100) |
Moz Domain Authority 34/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
Kite Pharma has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "Kite is dedicated to curing cancer. Learn about the science of cell therapy, our cancer research, and our cancer treatments in the pipeline." (Meta description: 23 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare.
Social footprint: verified profiles on X (Twitter), LinkedIn, Facebook, Instagram, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Kite Pharma?", Claude could identify the brand as of October 2026. Kite Pharma is a biotechnology company, now part of Gilead Sciences, known for developing CAR T-cell therapies for cancer, including Yescarta and Tecartus for certain blood cancers. Note that the website provided, arcellx.com, actually belongs to Arcellx, a different cell therapy Best known for Pioneering CAR T-cell therapies like Yescarta for treating lymphoma.
When asked "Best brands similar to Kite Pharma?", Claude would recommend Kite Pharma as of October 2026. Kite Pharma is a well known leader in CAR T-cell cancer therapy and would naturally come up alongside companies like Novartis or Bristol Myers Squibb in that space.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Kite Pharma's main competitors in Healthcare: Novartis (75/100), Bristol Myers Squibb (89/100), Legend Biotech (80/100), Janssen (Johnson & Johnson) (84/100), Autolus Therapeutics (79/100).
Sources: Brand Analyzer scan
Kite Pharma is a biomedical engineering company that develops cancer immunotherapy products, specifically personalized CAR T-cell therapies. Founded in 2009 and headquartered in Santa Monica, California, Kite is a subsidiary of Gilead Sciences. The company is dedicated to curing cancer through innovative cell therapy, focusing on treatments for blood cancers such as lymphoma.
Sources: Kite Pharma official site
Kite Pharma has moderate AI-search visibility, scoring 50/100 on Brand Analyzer's AI visibility composite (visibility 63, trust 29, recommendation 52). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Kite Pharma official site
Kite Pharma was founded in 2009. Kite Pharma operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Kite Pharma is headquartered in Santa Monica. Kite Pharma operates in the Healthcare category.
Sources: Wikidata
Kite Pharma offers cancer immunotherapy products, specifically personalized CAR T-cell therapies designed to treat blood cancers such as lymphoma. These treatments involve modifying a patient's own immune cells to target and attack cancer cells. The company also maintains a pipeline of additional cancer treatments under research and development.
Sources: Kite Pharma official site
Kite Pharma develops personalized CAR T-cell therapies, a form of cell therapy that engineers a patient's own immune cells to recognize and attack cancer. The company conducts cancer research and maintains a pipeline of cancer treatments aimed at transforming how cancer is treated, with the goal of achieving cures rather than simply managing disease progression.
Sources: Kite Pharma official site
Kite Pharma scores 52/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Kite Pharma official site
Kite Pharma can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Kite Pharma official site
Kite Pharma is owned by or part of Gilead Sciences. Kite Pharma operates in the Healthcare category.
Sources: Wikidata
Kite Pharma is known for pioneering CAR T-cell therapy, a personalized cancer treatment approach that reprograms a patient's own immune cells to target cancer. The company is recognized within the oncology field for its singular focus on cell therapy innovation for blood cancers, particularly lymphoma, as part of its broader mission to cure cancer.
Sources: Kite Pharma official site
Kite Pharma's therapies are used by cancer patients, particularly those with blood cancers such as lymphoma, who may not have responded to traditional treatments. The company's work also serves the needs of patients' families and caregivers, as well as the oncology medical community, including physicians and researchers involved in administering and studying cell therapy treatments.
Sources: Kite Pharma official site
Kite Pharma scores 50/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Kite Pharma has a limited AI-visibility profile at 50/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (63/100) and its weakest is trust (29/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: a low Moz Domain Authority of 34/100 and thin schema.org structured data. In a live check, Claude could already identify Kite Pharma from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Kite Pharma: Applied Research Associates (ARA) (82/100), Aquatabs (82/100), Archer Review (82/100), ARCH Venture Partners (82/100).
A step up - brands to learn from: Zoetis (91/100), theSkimm (91/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.